ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC director Jonathan Poole reported equity compensation activity, including option exercises and new awards. He exercised derivative securities for 2,010 shares of common stock and now holds 2,010 common shares directly. He also received 9,311 restricted stock units and 16,004 director stock options.

The 9,311 restricted stock units each represent a right to one share of common stock and will vest in full on the earlier of one year from grant or the next annual stockholder meeting, with settlement deferred based on his election. The 16,004 stock options vest quarterly over one year following the grant date and have an exercise price of $21.66 per share.

Insights

Equity compensation analyst

Routine director equity grants and an option-related share acquisition are reported, with no open-market buying or selling.

Director Jonathan Poole acquired equity in ACADIA PHARMACEUTICALS INC entirely through compensation mechanisms. He exercised derivative securities into 2,010 shares of common stock and received new awards of 9,311 RSUs and 16,004 stock options at an exercise price of $21.66 per share.

The filing shows all transactions as grants or exercises, without any open-market purchases or sales, which is typical for board compensation. The RSUs vest on the earlier of one year from grant or the next annual stockholder meeting, while options vest quarterly over a year, concentrating key vesting events through about 2027. Overall, this appears to be standard director compensation rather than a directional trading signal.

Insider Trade Summary

2,010 shares exercised/converted

Mixed 4 txns

Insider Poole Jonathan

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,010	$0.00	--
Grant/Award	Director Stock Options (Right to Buy)	16,004	$0.00	--
Grant/Award	Restricted Stock Units	9,311	$0.00	--
Exercise	Common Stock	2,010	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Director Stock Options (Right to Buy) — 16,004 shares (Direct, null); Common Stock — 2,010 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.

Key Figures

Common shares acquired: 2,010 shares RSUs granted: 9,311 units Stock options granted: 16,004 options +2 more

5 metrics

Common shares acquired 2,010 shares Shares of common stock held directly following derivative exercise

RSUs granted 9,311 units Restricted stock units representing rights to ACAD common shares

Stock options granted 16,004 options Director stock options granted on 2026-05-29

Option exercise price $21.66 per share Exercise price for 16,004 director stock options

RSU-to-share ratio 1:1 Each RSU represents one share of common stock

Key Terms

restricted stock unit, stock option, change in control, Equity Incentive Plan

4 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

stock option financial

"The shares subject to each stock option will vest quarterly over one year following the date of grant"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

change in control financial

"and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Equity Incentive Plan financial

"change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poole Jonathan

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/29/2026		M		2,010	A	(1)	2,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/29/2026		M			2,010	(2)	(2)	Common Stock	2,010	$0	0	D
Director Stock Options (Right to Buy)	$21.66	05/29/2026		A		16,004		(3)	05/28/2036	Common Stock	16,004	$0	16,004	D
Restricted Stock Units	(1)	05/29/2026		A		9,311		(4)	(4)	Common Stock	9,311	$0	9,311	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.

3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ACAD director Jonathan Poole report in this Form 4 for ACAD?

Jonathan Poole reported equity compensation activity, not open-market trades. He exercised derivative securities into 2,010 shares of ACAD common stock and received 9,311 restricted stock units plus 16,004 director stock options as part of his board compensation package.

How many ACADIA PHARMACEUTICALS (ACAD) shares did Jonathan Poole acquire?

Jonathan Poole acquired 2,010 shares of ACAD common stock through exercising derivative securities. These shares reflect settlement of previously granted restricted stock units, rather than new open-market purchases, and are now reported as directly owned common stock in his Form 4 filing.

What restricted stock unit awards did Jonathan Poole receive from ACAD?

Poole received 9,311 restricted stock units, each representing a right to one ACAD common share. These RSUs will vest in full on the earlier of one year from grant or the next annual stockholder meeting, with timing and settlement terms described in the compensation footnotes.

What stock options were granted to Jonathan Poole by ACADIA PHARMACEUTICALS?

Poole was granted 16,004 director stock options with an exercise price of $21.66 per share. The options vest quarterly over one year following the grant date, with the final tranche vesting by the earlier of one year from grant or the next annual stockholder meeting.

Does Jonathan Poole’s Form 4 for ACAD include any stock sales?

The Form 4 shows no open-market sales for Jonathan Poole. All reported transactions are coded as derivative exercises or grants, meaning they involve vesting or awards of equity compensation rather than discretionary buying or selling of ACAD shares in the market.